Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

Vaccine

Volumn 18, Issue 24, 2000, Pages 2693-2697

  Humphreys, R E ^a   Adams, S ^a   Koldzic, G ^a   Nedelescu, B ^a   Von Hofe, E ^a   Xu, M ^a  

^a Antigen Express   (United States)

Author keywords

Hybrids; Ii key peptide; MHC class II; Peptide vaccines

Indexed keywords

EPITOPE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; GENE CONSTRUCT; HUMAN; HUMAN CELL; IN VITRO STUDY; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

EID: 0034212481     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00067-0     Document Type: Article

References (16)

1. Adams S., Jackson R., Barbon C., Deng H., Koldzic G., Alsina J., et al. Immunosuppression and antigen supercharging by Ii-Key peptide-related compounds - a new class of drugs controlling the first step in antigen recognition. Current Res. Rheum. Arthritis. 2:1998;1-6.
2. Avva R.R., Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity. 1:1994;763-774.
3. Elliott W.L., Stille C.J., Thomas L.J., Humphreys R.E. An hypothesis on the binding of an amphipathic, alpha helical sequence in Ii to the desetope of Class II antigens. J. Immun. 138:1987;2949-2952.
4. Daibata M., Xu M., Humphreys R.E., Reyes V.E. More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release. Mol. Immun. 31:1994;255-260.
5. Xu M., Capraro G.A., Daibata M., Reyes V.E., Humphreys R.E. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. Mol. Immun. 31:1994;723-731.
6. Xu M., Daibata M., Adams S., Humphreys R.E., Reyes V.E. Charging of peptides to MHC Class II molecules during proteolysis of Ii. Humphreys R.E., Pierce S.K. Antigen processing and presentation. 1994;227-241 Academic Press, San Diego, CA.
7. Lu S., Ciardelli T., Reyes V.E., Humphreys R.E. Number and placement of hydrophobic residues in a longitudinal strip govern helix formation of peptides in the presence of lipid vesicles. J. Biol. Chem. 266:1991;10,054-10,057.
8. Adams S., Humphreys R.E. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur. J. Immun. 25:1995;1693-1702.
9. Adams S., Albericio F., Alsina J., Smith E.R., Humphreys R.E. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arznei-Forsch. 47:1997;1069-1077.
10. Xu M., Jackson R., Adams S., Humphreys R.E. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR-1. Arznei-Forsch. 49:1999;791-799.
11. Ghosh P., Amaya M., Mellins E., Wiley D.C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature. 378:1995;457-462.
12. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 368:1994;215-221.
13. Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J., Vignali D.A., et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature. 358:1992;764-768.
14. Feng S., Chen J.K., Yu H., Simon J.A., Schreiber S.L. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science. 266:1994;1241-1247.
15. Rosenthal K.S., Mao H., Horne W.I., Wright C., Zimmerman D. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine. 17:1999;535-542.
16. Hess A., Horwitz L., Thoburn C. Immune tolerance to self-MHC class II antigens after bone marrow transplantation. Transplant Proc. 31:1999;688-689.